ARAY - Accuray Incorporated
3.61 0.00 (0.00%)
After hours: 4:43PM EDT
| Previous Close | 3.69 |
| Open | 3.69 |
| Bid | 3.60 x 3000 |
| Ask | 4.75 x 3000 |
| Day's Range | 3.59 - 3.73 |
| 52 Week Range | 3.20 - 6.15 |
| Volume | 558,006 |
| Avg. Volume | 684,560 |
| Market Cap | 312.253M |
| Beta (3Y Monthly) | 2.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.•2 days ago
Who Are The Major Shareholders In Accuray Incorporated (NASDAQ:ARAY)?
The big shareholder groups in Accuray Incorporated (NASDAQ:ARAY) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions Read More...
- Zacks•4 days ago
Varian (VAR) Buys Noona to Boost Oncology Software Services
Varian's (VAR) latest move provides it significant exposure to the cloud-based oncology services market.
- Zacks•10 days ago
Accuray's (ARAY) Radixact System Used First Time in Germany
Accuray's (ARAY) flagship radiotherapy systems have lucrative prospects.
- Zacks•23 days ago
Accuray's CyberKnife Manages Prostate Cancer Effectively
Accuray's (ARAY) flagship CyberKnife is the only robotic radiotherapy system.
- Simply Wall St.•last month
A Look At The Fair Value Of Accuray Incorporated (NASDAQ:ARAY)
How far off is Accuray Incorporated (NASDAQ:ARAY) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...
Market Realist•2 months agoHere’s What Varian Medical Systems’ Valuation Trend Indicates
In August, nine analysts are covering Varian Medical Systems (VAR) stock. Three of them have given the stock a “strong buy” rating, three have given it a “hold,” and three have given it a “sell.” The mean rating for VAR stock is 2.67 with a target price of $122. That implies an upside potential of 9.1% over its closing price of $111.83 on August 20.
- Motley Fool•2 months ago
Why Zoe's Kitchen, America's Car-Mart, and Accuray Jumped Today
On a positive day for the markets, see why these three stocks outpaced the rest.
- Motley Fool•2 months ago
Why Accuray Is Soaring Today
Shares pop after the company reports upbeat fourth-quarter results. Here's what investors need to know.
- Zacks•4 months ago
Accuray's Radixact Gets AERB Nod in India, Prospects Solid
The Atomic Energy Regulatory Board (AERB) approves Accuray's (ARAY) Radixact X9 in India; exposes the company to AI and Mechatronic trends.
- Simply Wall St.•4 months ago
At US$04.325, Is It Time To Buy Accuray Incorporated (NASDAQ:ARAY)?
Accuray Incorporated (NASDAQ:ARAY), a medical equipment company based in United States, received a lot of attention from a substantial price movement on the NasdaqGS over the last few months, increasingRead More...
- Zacks•4 months ago
New Strong Sell Stocks for June 11th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Zacks•5 months ago
Here's Why You Should Sell Accuray (ARAY) Stock Right Now
Regulatory issues regarding Onrad, intense competition in the radiation oncology market and unfavorable foreign exchange rate are significant challenges for Accuray (ARAY).
- Zacks•5 months ago
New Strong Sell Stocks for June 4th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Zacks•5 months ago
Accuray (ARAY) Down 13.7% Since Earnings Report: Can It Rebound?
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool•5 months ago
Why Accuray, Cincinnati Bell, and Chesapeake Energy Slumped Today
Find out which company dealt with weak earnings.
- Zacks•5 months ago
New Strong Sell Stocks for May 23rd
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Zacks•5 months ago
New Strong Sell Stocks for May 17th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Zacks•6 months ago
Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top
Radixact System and major software overhaul drive Accuray (ARAY) in Q3.
- Zacks•7 months ago
Accuray Radixact Picked by India's Apollo for Cancer Treatment
Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.
- Zacks•7 months ago
Accuray's CyberKnife Treats First Patient at Erasmus MC
Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.
- Zacks•7 months ago
Accuray Banks on Acquisition & Partnership Amid Competition
Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.
- Zacks•7 months ago
Accuray Gains on Radixact Unit, Solid Geographical Foothold
Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).
- Zacks•7 months ago
Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session
The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.
- Market Realist•8 months ago
How Accuray Has Performed Financially
In 2Q18, Accuray’s (ARAY) net revenues were $100.3 million compared with $87.5 million in 2Q17. Its total revenues come from product sales and services provided. Product sales grew from $35.3 million in 2Q17 to $47.1 million in 2Q18.
Market Realist•8 months agoHow Much Is Accuray’s Target Market Expected to Grow?
To increase physician adoption and patient awareness of its systems, Accuray (ARAY) holds and sponsors symposia and educational meetings and educates clinicians about its systems. Accuray focuses on innovation through clinical development and collaboration and seeks constructive feedback from its system users to enhance the company’s product offerings. Accuray endeavors to expand sales in international markets. According to the World Health Organization (or WHO), cancer is the second-leading cause of death worldwide.
